



RECEIVED

JUN 26 2002

TECH CENTER 1600/2900

Docket No.: 197679US0PCT

ASSISTANT COMMISSIONER FOR PATENTS
WASHINGTON, D.C. 20231

OBLON
SPIVAK
McCLELLAND
MAIER
&
NEUSTADT
P.C.

ATTORNEYS AT LAW

NORMAN F. OBLON
(703) 413-3000
NOBLON@OBLON.COM

VINCENT K. SHIER, PH.D.
REGISTERED PATENT AGENT
(703) 413-3000
VSHIER@OBLON.COM

RE: Application Serial No.: 09/646,899
Applicants: Tomoko MAEDA, et al.
Filing Date: October 10, 2000
For: METHODS FOR ISOLATION OF OSTEOCLAST
PRECURSOR CELLS AND INDUCING THEIR
DIFFERENTIATION INTO OSTEOCLASTS
Group Art Unit: 1651
Examiner: AFREMOVA

SIR:

Attached hereto for filing are the following papers:

**Response to Restriction
International Preliminary Examination Report
Appendix**

Our check in the amount of \$0.00 is attached covering any required fees. In the event any variance exists between the amount enclosed and the Patent Office charges for filing the above-noted documents, including any fees required under 37 C.F.R. 1.136 for any necessary Extension of Time to make the filing of the attached documents timely, please charge or credit the difference to our Deposit Account No. 15-0030. Further, if these papers are not considered timely filed, then a petition is hereby made under 37 C.F.R. 1.136 for the necessary extension of time. A duplicate copy of this sheet is enclosed.

Respectfully submitted,

OBLON, SPIVAK, McCLELLAND,
MAIER & NEUSTADT, P.C.

Norman F. Oblon
Attorney of Record
Registration No. 24,618



22850

(703) 413-3000 (phone)
(703) 413-2220 (fax)

Vincent K. Shier, Ph.D.
Registration No. 50,552

DOCKET NO.: 197679US0PCT



IN THE UNITED STATES PATENT & TRADEMARK OFFICE

IN RE APPLICATION OF:

Tomoko MAEDA, et al. : GROUP ART UNIT: 1651

SERIAL NO.: 09/646,899 :

FILED: OCTOBER 10, 2000 : EXAMINER: AFREMOVA

FOR: METHODS FOR ISOLATION OF OSTEOCLAST PRECURSOR CELLS AND INDUCING THEIR DIFFERENTIATION INTO OSTEOCLASTS

RESPONSE TO RESTRICTION

In response to the Official Action dated May 23, 2002, Applicants elect, with traverse, Group I, Claims 1-4 and 8-11, for further prosecution.

REMARKS

The Office has required restriction in the present application as follows:

Group I: Claims 1-4 and 8-11, drawn to a method for differentiating osteoclast precursor cells;

Group II: Claims 5 and 6, drawn to a method for isolating osteoclast precursor cells;

Group III: Claim 7, drawn to an osteoclast precursor cell; (undif. form unseen)

Group IV: Claim 12, drawn to an osteoclast cell; (differentiated cell)

Group V: Claims 13, 14, and 18, drawn to a method for screening agents by using osteoclast precursor cells;

Group VI: Claims 15, 16, and 19, drawn to a method for screening agents by using osteoclast precursor cells; and
just osteoclast in claim !!!

Group VII: Claim 17, drawn to an agent for metabolic bone diseases.

See
intention
summary
5/20/02

TECH CENTER 1600/2000

JUN 26 2002

RECEIVED

STC US
5/20/02